Alessio Ciulli holds the Personal Chair of Chemical and Structural Biology at the School of Life Sciences, University of Dundee. His laboratory focuses on developing small molecules inducing protein degradation and targeting protein-protein interactions (PPIs). His group’s significant discoveries jump-started the PROTAC field and led to significant commercial impact across academia and biopharma worldwide. He is the scientific founder of Amphista therapeutics, a company that develops new protein degradation platforms. Alessio graduated in Chemistry from his hometown Florence, Italy (2002) and obtained a PhD in Chemical Biology from Cambridge, UK (2006). Following post-doctoral research at Cambridge, and a brief visit at Yale University, he returned to Cambridge in 2009 to start his independent career. In 2013 Alessio moved his laboratory to Dundee and was promoted to Full Professor in 2016. He is a Fellow of the Royal Society of Chemistry and recipient of several prestigious awards.